Thirty jobs to be created in DCU pharmaceutical enterprise

Up to 30 highly-skilled pharmaceutical jobs are to be created in Dublin, it was announced today.

It follows the takeover of an innovative Dublin City University (DCU) start-up enterprise by a major European company.

Archport was set up at the university in 1998 to offer contract production and development services for the biopharmaceutical industry.

German-based Uetikon who has taken an 80% stake in the business said it will provide significant investment, including 30 new bio-processing jobs, as part of an overall expansion scheme.

The company already has purpose-built biopharmaceutical laboratories on the DCU campus. The university is to retain a 20% share in the venture.

Professor Martin Clynes, founder of Archport, said: “This success vindicates the support given by DCU and Bioresearch Ireland in the 1980s to what was then a very new area of research.”

He added: “It also illustrates the important impact that government support for research centres such as National Institute for Cellular Biotechnology can have on economic development.”

Uetikon chief executive officer Dr Heinz Sieger praised DCU for its innovation and world-class biotechnology research.

More in this Section

Leading economist Alan McQuaid steps down for new role

Ulster Bank customers to be charged every time they use their card

Board set up to improve banking culture 'rigged' in industry's favour: John McGuinnness

No Consent, No Sale bill 'should be no-brainer'


Lifestyle

Wish List: Mellow yellow in the bedroom and beyond

10 ways to help protect your child’s online reputation

Lindsay Woods: Easter break is like the amuse-bouche to the main event, the summer holidays

Birth of Modernism in Irish art

More From The Irish Examiner